{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:53:54Z","timestamp":1790409234873,"version":"4.1.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,15]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The role of measurable residual disease (MRD) negativity as a biomarker to stop treatment is being investigated in transplant-eligible patients with multiple myeloma (MM). Thus, it is important to identify risk factors of MRD resurgence and\/or progressive disease (PD) among patients achieving undetectable MRD to avoid undertreating them. Here, we studied 267 newly diagnosed transplant-eligible patients with MM enrolled in the GEM2012MENOS65 and GEM2014MAIN clinical trials who achieved MRD negativity by next-generation flow cytometry. After a median follow-up of 73 months since the first MRD negative assessment, 111 of the 267 (42%) patients showed MRD resurgence and\/or PD. The only prognostic factors at diagnosis that predicted MRD resurgence and\/or PD were an International Staging System (ISS) 3 and the presence of \u22650.01% circulating tumor cells (CTCs). Failure to achieve MRD negativity after induction also predicted higher risk of MRD resurgence and\/or PD. Patients having 0 vs 1 vs \u22652 risk factors (ISS 3, \u22650.01% CTCs, and late MRD negativity) showed 5-year rates of MRD resurgence and\/or PD of 16%, 33%, and 57%, respectively (P\u00a0&amp;lt; .001). Thus, these easily measurable risk factors could help refine the selection of patients for whom treatment cessation after MRD negativity is being investigated in clinical trials. This trial was registered at www.clinicaltrials.gov as NCT01916252 and NCT02406144.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023022083","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T21:41:16Z","timestamp":1701726076000},"page":"597-603","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":40,"title":["Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1395-5140","authenticated-orcid":false,"given":"Camila","family":"Guerrero","sequence":"first","affiliation":[{"name":"1Cancer Center Cl\u00ednica Universidad de Navarra, Centro de Investigaci\u00f3n M\u00e9dica Aplicada, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBER-ONC) number CB16\/12\/00369, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7535-3861","authenticated-orcid":false,"given":"Noemi","family":"Puig","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Hospital Universitario de Salamanca Hematolog\u00eda, Instituto de investigaci\u00f3n Biom\u00e9dica de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5851-3720","authenticated-orcid":false,"given":"Mar\u00eda-Teresa","family":"Cedena","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0374-3008","authenticated-orcid":false,"given":"Mar\u00eda-Jos\u00e9","family":"Calasanz","sequence":"additional","affiliation":[{"name":"1Cancer Center Cl\u00ednica Universidad de Navarra, Centro de Investigaci\u00f3n M\u00e9dica Aplicada, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBER-ONC) number CB16\/12\/00369, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5834-9510","authenticated-orcid":false,"given":"Norma C.","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Hospital Universitario de Salamanca Hematolog\u00eda, Instituto de investigaci\u00f3n Biom\u00e9dica de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Fernandez","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-2221","authenticated-orcid":false,"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Institut Catal\u00e0 d'Oncologia L\u2019Hospitalet, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8193-1402","authenticated-orcid":false,"given":"Rafael","family":"R\u00edos-Tamayo","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6576-7881","authenticated-orcid":false,"given":"Miguel-Teodoro","family":"Hernandez","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Mart\u00ednez-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Hospital Universitario San Carlos, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Bargay","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Hospital Universitario Son Llatzer, Institut d\u2019Investigacio Illes Balears, Palma de Mallorca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"de Arriba","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Hospital Morales Meseguer, Instituto Murciano de Investigaci\u00f3n Biosanitaria-Pascual Parrilla, Universidad de Murcia, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Palomera","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Hospital Cl\u00ednico Lozano Blesa, Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0565-9133","authenticated-orcid":false,"given":"Ana Pilar","family":"Gonzalez-Rodriguez","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Hospital Central de Asturias, Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta-Sonia","family":"Gonzalez Perez","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Complejo Hospitalario Universitario de Santiago de Compostela, Servizio Galego de Sa\u00fade, Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Orfao","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Hospital Universitario de Salamanca Hematolog\u00eda, Instituto de investigaci\u00f3n Biom\u00e9dica de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Hospital Universitario de Salamanca Hematolog\u00eda, Instituto de investigaci\u00f3n Biom\u00e9dica de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Martinez-Lopez","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2534-9239","authenticated-orcid":false,"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Hospital Cl\u00ednic, Institut de Recerca Biomedica August Pi i Su\u00f1er, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Hospital Cl\u00ednic, Institut de Recerca Biomedica August Pi i Su\u00f1er, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3393-9570","authenticated-orcid":false,"given":"Juan-Jose","family":"Lahuerta","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-4857","authenticated-orcid":false,"given":"Jesus F.","family":"San-Miguel","sequence":"additional","affiliation":[{"name":"1Cancer Center Cl\u00ednica Universidad de Navarra, Centro de Investigaci\u00f3n M\u00e9dica Aplicada, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBER-ONC) number CB16\/12\/00369, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-3815","authenticated-orcid":false,"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[{"name":"1Cancer Center Cl\u00ednica Universidad de Navarra, Centro de Investigaci\u00f3n M\u00e9dica Aplicada, Instituto de Investigaci\u00f3n Sanitaria de Navarra, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBER-ONC) number CB16\/12\/00369, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"20","key":"2024021516283462100_bib1","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2024021516283462100_bib2","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A\u00a0large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2024021516283462100_bib3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Minimal residual disease predicts superior survival in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"23","key":"2024021516283462100_bib4","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2024021516283462100_bib5","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.622","article-title":"Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis","volume":"20","author":"Avet-Loiseau","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2024021516283462100_bib6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-020-00911-4","article-title":"Measurable residual disease in multiple myeloma: ready for clinical practice?","volume":"13","author":"Burgos","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"6","key":"2024021516283462100_bib7","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.2021011101","article-title":"Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA MA","volume":"139","author":"Cavo","year":"2022","journal-title":"Blood"},{"issue":"25","key":"2024021516283462100_bib8","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"2024021516283462100_bib9","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1200\/JCO.21.02228","article-title":"Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk","volume":"40","author":"De Tute","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"2024021516283462100_bib10","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2024021516283462100_bib11","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1200\/JCO.20.01814","article-title":"Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and\/or refractory multiple myeloma: analysis of POLLUX and CASTOR","volume":"39","author":"Avet-Loiseau","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024021516283462100_bib12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1470-2045(22)00738-0","article-title":"Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Dytfeld","year":"2023","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"2024021516283462100_bib13","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S2152-2650(22)00284-1","article-title":"OAB-011: Predictors of unsustained negativity in minimal residual disease (MRD)-negative transplant-eligible newly diagnosed multiple myeloma (MM) patients enrolled in the FORTE trial","volume":"22","author":"D\u2019Agostino","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2024021516283462100_bib14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood.2022016782","article-title":"MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials","volume":"141","author":"Paiva","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2024021516283462100_bib15","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1016\/j.clml.2023.02.005","article-title":"Association of minimal residual disease negativity rates with progression free survival in frontline therapy trials for newly diagnosed multiple myeloma: a meta-analysis","volume":"23","author":"Ficek","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"16","key":"2024021516283462100_bib16","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Rosi\u00f1ol","year":"2019","journal-title":"Blood"},{"issue":"18","key":"2024021516283462100_bib17","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/blood.2022019531","article-title":"Lenalidomide and dexamethasone with or without ixazomib maintenance tailored by residual disease status in myeloma","volume":"142","author":"Rosi\u00f1ol","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2024021516283462100_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-018-0153-9","article-title":"Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)","volume":"8","author":"Sanoja-Flores","year":"2018","journal-title":"Blood Cancer J"},{"issue":"10","key":"2024021516283462100_bib19","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow (NGF) for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"27","key":"2024021516283462100_bib20","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"issue":"27","key":"2024021516283462100_bib21","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1200\/JCO.21.01365","article-title":"Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma","volume":"40","author":"Garc\u00e9s","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2024021516283462100_bib22","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.21.01393","article-title":"High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"40","author":"Bertamini","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024021516283462100_bib23","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"San-Miguel","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2024021516283462100_bib24","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1182\/bloodadvances.2020003996","article-title":"Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches","volume":"5","author":"Lahuerta","year":"2021","journal-title":"Blood Adv"},{"issue":"9","key":"2024021516283462100_bib25","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jamaoncol.2022.2424","article-title":"Elotuzumab and weekly carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma without transplant intent","volume":"8","author":"Derman","year":"2022","journal-title":"JAMA Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/7\/597\/2213719\/blood_bld-2023-022083-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/7\/597\/2213719\/blood_bld-2023-022083-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T16:29:09Z","timestamp":1708014549000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/7\/597\/506497\/Predictors-of-unsustained-measurable-residual"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,2,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023022083","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,15]]}}}